These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22828320)

  • 1. Investigation on PLK2 and PLK3 substrate recognition.
    Salvi M; Trashi E; Cozza G; Franchin C; Arrigoni G; Pinna LA
    Biochim Biophys Acta; 2012 Dec; 1824(12):1366-73. PubMed ID: 22828320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Acidophilic Kinases PLK2 and PLK3: Structure, Substrate Targeting and Inhibition.
    Cozza G; Salvi M
    Curr Protein Pept Sci; 2018; 19(8):728-745. PubMed ID: 29366414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tools to discriminate between targets of CK2 vs PLK2/PLK3 acidophilic kinases.
    Salvi M; Trashi E; Cozza G; Negro A; Hanson PI; Pinna LA
    Biotechniques; 2012 Jul; 53(1):. PubMed ID: 26307252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3.
    Reindl W; Gräber M; Strebhardt K; Berg T
    Anal Biochem; 2009 Dec; 395(2):189-94. PubMed ID: 19716361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorylation of synucleins by members of the Polo-like kinase family.
    Mbefo MK; Paleologou KE; Boucharaba A; Oueslati A; Schell H; Fournier M; Olschewski D; Yin G; Zweckstetter M; Masliah E; Kahle PJ; Hirling H; Lashuel HA
    J Biol Chem; 2010 Jan; 285(4):2807-22. PubMed ID: 19889641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plk3 phosphorylates topoisomerase IIalpha at Thr(1342), a site that is not recognized by Plk1.
    Iida M; Matsuda M; Komatani H
    Biochem J; 2008 Apr; 411(1):27-32. PubMed ID: 18062778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain.
    Bergeron M; Motter R; Tanaka P; Fauss D; Babcock M; Chiou SS; Nelson S; San Pablo F; Anderson JP
    Neuroscience; 2014 Jan; 256():72-82. PubMed ID: 24128992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Finding Plk3.
    Zimmerman WC; Erikson RL
    Cell Cycle; 2007 Jun; 6(11):1314-8. PubMed ID: 17568195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polo-like kinases and oncogenesis.
    Eckerdt F; Yuan J; Strebhardt K
    Oncogene; 2005 Jan; 24(2):267-76. PubMed ID: 15640842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach.
    Kumar M; Pydi SP; Sharma S; Singh TP; Kaur P
    J Mol Graph Model; 2014 Jun; 51():104-12. PubMed ID: 24879322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
    Johnson EF; Stewart KD; Woods KW; Giranda VL; Luo Y
    Biochemistry; 2007 Aug; 46(33):9551-63. PubMed ID: 17655330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structure of the polo-box domain of polo-like kinase 2.
    Shan HM; Wang T; Quan JM
    Biochem Biophys Res Commun; 2015 Jan; 456(3):780-4. PubMed ID: 25511705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal induction of polo-like kinases (Plks) and impact of Plk2 on cell cycle progression in the rat ovary.
    Li F; Jo M; Curry TE; Liu J
    PLoS One; 2012; 7(8):e41844. PubMed ID: 22870256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the PLK2-dependent phosphopeptidome by quantitative proteomics [corrected].
    Franchin C; Cesaro L; Pinna LA; Arrigoni G; Salvi M
    PLoS One; 2014; 9(10):e111018. PubMed ID: 25338102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects.
    Liu Y; Jiang N; Wu J; Dai W; Rosenblum JS
    J Biol Chem; 2007 Jan; 282(4):2505-11. PubMed ID: 17135248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polo-like kinase 3 (PLK3) mediates the clearance of the accumulated PrP mutants transiently expressed in cultured cells and pathogenic PrP(Sc) in prion infected cell line via protein interaction.
    Wang H; Tian C; Fan XY; Chen LN; Lv Y; Sun J; Zhao YJ; Zhang LB; Wang J; Shi Q; Gao C; Chen C; Shao QX; Dong XP
    Int J Biochem Cell Biol; 2015 May; 62():24-35. PubMed ID: 25724737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polo-like kinases in the nervous system.
    Seeburg DP; Pak D; Sheng M
    Oncogene; 2005 Jan; 24(2):292-8. PubMed ID: 15640845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polo-box domains confer target specificity to the Polo-like kinase family.
    van de Weerdt BC; Littler DR; Klompmaker R; Huseinovic A; Fish A; Perrakis A; Medema RH
    Biochim Biophys Acta; 2008 Jun; 1783(6):1015-22. PubMed ID: 18359294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium- and integrin-binding protein 1 regulates microtubule organization and centrosome segregation through polo like kinase 3 during cell cycle progression.
    Naik MU; Naik UP
    Int J Biochem Cell Biol; 2011 Jan; 43(1):120-9. PubMed ID: 20951827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma.
    Pellegrino R; Calvisi DF; Ladu S; Ehemann V; Staniscia T; Evert M; Dombrowski F; Schirmacher P; Longerich T
    Hepatology; 2010 Mar; 51(3):857-68. PubMed ID: 20112253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.